CAJ | 학술논문

目的：：评价经尿道膀胱肿瘤等离子电切术( PKRBT)与经尿道膀胱肿瘤钬激光切除术( HOLRBT)治疗非肌层浸润性膀胱侧壁肿瘤的疗效及安全性。方法：将60例非肌层浸润性膀胱侧壁肿瘤患者随机分为HOLRBT组与PKRBT组各30例,分别对2组患者手术时间、术中失血量、膀胱冲洗时间、尿管留置时间、住院时间、手术并发症及术后2年肿瘤复发率进行比较分析。结果：HOLRBT组在手术时间、术中失血量、膀胱冲洗时间、尿管留置时间、住院时间及术后并发症的发生率均低于PKRBT组(P<0．05)；术后2年肿瘤复发率HOLRBT组为23．33%,PKRBT组为43．33%,2组比较无显著性差异(P>0．05)；但其中肿瘤原位复发率HOLRBT组为6．67%,PKRBT组为26．67%,2组比较有显著性差异(P<0．05)。结论：经尿道膀胱肿瘤等离子电切术与经尿道膀胱肿瘤钬激光切除术均是治疗非肌层浸润性膀胱肿瘤的常用方法,但HOLRBT手术易掌握、安全性高及并发症少,特别对于膀胱侧壁肿瘤术后肿瘤原位复发率明显减少,值得临床推广使用。
목적：：평개경뇨도방광종류등리자전절술( PKRBT)여경뇨도방광종류화격광절제술( HOLRBT)치료비기층침윤성방광측벽종류적료효급안전성。방법：장60례비기층침윤성방광측벽종류환자수궤분위HOLRBT조여PKRBT조각30례,분별대2조환자수술시간、술중실혈량、방광충세시간、뇨관류치시간、주원시간、수술병발증급술후2년종류복발솔진행비교분석。결과：HOLRBT조재수술시간、술중실혈량、방광충세시간、뇨관류치시간、주원시간급술후병발증적발생솔균저우PKRBT조(P<0．05)；술후2년종류복발솔HOLRBT조위23．33%,PKRBT조위43．33%,2조비교무현저성차이(P>0．05)；단기중종류원위복발솔HOLRBT조위6．67%,PKRBT조위26．67%,2조비교유현저성차이(P<0．05)。결론：경뇨도방광종류등리자전절술여경뇨도방광종류화격광절제술균시치료비기층침윤성방광종류적상용방법,단HOLRBT수술역장악、안전성고급병발증소,특별대우방광측벽종류술후종류원위복발솔명현감소,치득림상추엄사용。
Objective:To compare the efficacy and safety of transurethral holmium laser resection ( HOLRBT ) with transurethral plasmakinetic resection( PKRBT) in patients with superficial bladder cancer in Sidewall. Methods:60 patients with NMIBT were divided into HOLRBT group ( n =30 ) and PKRBT group ( n =30 ) . The operative time, the blood loss, bladder irrigation time,hospitalization time,complication and tumor recurrence rate of 2 years were analyzed. Results:The operative time, the blood loss, bladder irrigation time, hospitalization time and the incidence of complications in the HOLRBT group were significantly lower than those in the PKRBT group ( P<0. 05 );the recurrence rate of tumor in 2 years in HOLRBT group was 23. 33%,in PKRBT group was 43. 33%,the difference was not statistically significant (P>0. 05);However,the recurrence rate of the tumor in situ in HOLRBT group was 6. 67%,in PKRBT group was 26. 67%,the difference was statistically significant( P<0. 05 ) . Conclusion:HOLRBT and PKRBT are the common method of treating non-muscle Invasive Bladder Tumor,but HOLRBT surgery is easy to apply,and safe and less complication,Especially for the recurrence rate of the tumor in situ is lower significantly in the HOLRBT group. It is worth the clinical promotion.